British cancer drug developer Ellipses Pharma considers London listing
17 hours ago
British cancer drug developer Ellipses Pharma plans to list on the London Stock Exchange via a reverse takeover with Wolfram Resources, targeting completion by early 2027 to fund its oncology pipeline.
